ADMA Biologics, Inc. (ADMA)
$
19.8
+0.41 (2.07%)
Key metrics
Financial statements
Free cash flow per share
0.2737
Market cap
4.7 Billion
Price to sales ratio
9.9380
Debt to equity
0.2104
Current ratio
5.3317
Income quality
0.3672
Average inventory
181.8 Million
ROE
0.6178
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics to address immune deficiencies and infectious diseases both in the United States and internationally. The company recorded a notable revenue of $426,454,000.00 showcasing its steady growth. Among its key offerings are BIVIGAM, an intravenous immune globulin (IVIG) product for treating primary humoral immunodeficiency (PI), ASCENIV, another IVIG product designed for the same condition, and Nabi-HB, indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen along with other potential exposures to Hepatitis B. Additionally, ADMA Biologics is developing a pipeline of plasma-derived therapeutics, including innovative products aimed at the treatment and prevention of S. pneumonia infections for immunoglobulin. The cost of revenue for the company is $206,901,000.00 showcasing its production and operational expenses, while the total costs and expenses for the company are $287,471,000.00 reflecting its overall spending. The company's stock is identified with the symbol 'ADMA' in the market, and the weighted average number of diluted shares outstanding is 243,342,000.00 indicating potential dilution effects. Moreover, the stock is affordable at $15.91 making it suitable for budget-conscious investors seeking opportunities. With a high average trading volume of 3,497,138.00 the stock demonstrates strong liquidity, which is an advantageous factor for traders. With a mid-range market capitalization of $4,712,355,565.00 the company is a steady performer in the biopharmaceutical realm. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth within the Healthcare sector. This dual focus on patient needs and robust market engagement aligns ADMA Biologics as an important entity shaping the future of plasma-derived therapeutics.
Is ADMA Biologics, Inc. (ADMA) a good investment?
Investing in ADMA Biologics, Inc. (ADMA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
What is ADMA Biologics, Inc. (ADMA)'s stock forecast?
Analysts predict ADMA Biologics, Inc. stock to fluctuate between $13.50 (low) and $25.67 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is ADMA Biologics, Inc.'s market capitalization?
As of 2025-12-08, ADMA Biologics, Inc.'s market cap is $4,712,355,565, based on 237,997,765 outstanding shares.
How does ADMA Biologics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., ADMA Biologics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy ADMA Biologics, Inc. (ADMA) stock?
To buy ADMA Biologics, Inc. (ADMA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ADMA. Place an order (Market, Limit, etc.).
What is the best time to invest in ADMA Biologics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did ADMA Biologics, Inc. perform in the last earnings report?
Revenue: $426,454,000 | EPS: $0.85 | Growth: -753.85%.
Where can I find ADMA Biologics, Inc.'s investor relations reports?
Visit https://www.admabiologics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for ADMA Biologics, Inc.?
You can explore historical data from here
What is the all-time high and low for ADMA Biologics, Inc. stock?
All-time high: $25.67 (2025-04-28) | All-time low: $1.01 (2021-10-21).
What are the key trends affecting ADMA Biologics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
defenseworld.net
Ardsley Advisory Partners LP lifted its position in ADMA Biologics Inc (NASDAQ: ADMA) by 33.3% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 400,000 shares of the biotechnology company's stock after purchasing an additional 100,000 shares during the quarter. Ardsley Advisory Partners
zacks.com
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
zacks.com
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
zacks.com
The consensus price target hints at a 60.2% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Here is how Adma Biologics (ADMA) and Cronos Group (CRON) have performed compared to their sector so far this year.
zacks.com
After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
seekingalpha.com
ADMA Biologics remains a Buy as Q3 results and 2026 guidance support a bullish long-term outlook. ADMA's Asceniv drives robust revenue and margin expansion, with 2026 revenue guided at $630M and EBITDA margin at 56%. Yield-enhanced manufacturing and facility expansion position ADMA for further growth, while SG-001 offers optionality beyond 2029.
zacks.com
From a technical perspective, Adma Biologics (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
zacks.com
Adma Biologics (ADMA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ADMA broke through the 50-day moving average, which suggests a short-term bullish trend.
See all news
